Presence of ERG positive and ERG negative subclones in the cancers of the vast majority of prostate cancer patients obviously challenges the classification of prostate cancers as “fusion-type” vs. “non-fusion type” on a patient level. This evidence concerns the gene ERG and Familial prostate cancer.